Global Communications

February 25, 2013

A Unique Partnership Develops A New Self-Injection Technology

At the 2013 Drug Delivery Partnership conference, West’s Bart Burgess partnered with Peter Krulevitch, Ph.D., Engineering Director, Packaging, Devices & Delivery, Janssen Pharmaceutical Companies of Johnson & Johnson to discuss West and Janssen’s unique partnership.  Together, West and Janssen are developing the SelfDoseTM injector platform technology.*

The partnership began as an effort to meet patient needs with a simple, friendly self-administration device that would deliver Janssen biologic drug products.  The product would need a reliable design that would be compatible with Janssen’s fill/finish infrastructure and easy to use for a range of patients.

Janssen has partnered with West to develop and manufacture the new SelfDose Injector Technology , an easy-to-use system designed for subcutaneous injection.

*For investigational use only for our pharmaceutical and biotechnology development partners; SelfDose [TM] has not been cleared or approved by the FDA as a standalone product.

SelfDose™ is a trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. West seeks partners for its SelfDose™ injector technology platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.